S'abonner

Mass drug administration of ivermectin and dihydroartemisinin–piperaquine against malaria in settings with high coverage of standard control interventions: a cluster-randomised controlled trial in The Gambia - 24/03/22

Doi : 10.1016/S1473-3099(21)00557-0 
Edgard D Dabira, MD a, , Harouna M Soumare, PharmD a, Bakary Conteh, MD a, Fatima Ceesay, MSc a, Mamadou O Ndiath, PhD a, John Bradley, PhD b, Nuredin Mohammed, PhD b, Balla Kandeh, MSc c, Menno R Smit, PhD d, e, Hannah Slater, PhD f, Koen Peeters Grietens, ProfPhD g, Henk Broekhuizen, PhD i, j, Teun Bousema, ProfPhD h, Chris Drakeley, ProfPhD b, Steve W Lindsay, ProfPhD k, Jane Achan, PhD a, Umberto D’Alessandro, ProfPhD a
a Medical Research Council Unit, London School of Hygiene & Tropical Medicine, Fajara, The Gambia 
b London School of Hygiene & Tropical Medicine, London, UK 
c National Malaria Control Program, Banjul, The Gambia 
d Amsterdam Centre for Global Child Health, Emma Children’s Hospital, Amsterdam University Medical Centres, Amsterdam, Netherlands 
e Liverpool School of Tropical Medicine, Liverpool, UK 
f PATH, Seattle, WA, USA 
g Department of Public Health, Medical Anthropology Unit, Institute of Tropical Medicine, Antwerp, Belgium 
h Radboud University Medical Centre, Nijmegen, Netherlands 
i Department of Health and Society, Wageningen University, Wageningen, Netherlands 
j Department of Health Evidence, Radboud University Medical Centre, Nijmegen, Netherlands 
k Department of Biosciences, Durham University, Durham, UK 

* Correspondence to: Dr Edgard D Dabira, Medical Research Council Unit, London School of Hygiene & Tropical Medicine, Fajara, The Gambia Medical Research Council Unit London School of Hygiene & Tropical Medicine Fajara The Gambia

Summary

Background

Although the malaria burden has substantially decreased in sub-Saharan Africa, progress has stalled. We assessed whether mass administration of ivermectin (a mosquitocidal drug) and dihydroartemisinin–piperaquine (an antimalarial treatment) reduces malaria in The Gambia, an area with high coverage of standard control interventions.

Methods

This open-label, cluster-randomised controlled trial was done in the Upper River region of eastern Gambia. Villages with a baseline Plasmodium falciparum prevalence of 7–46% (all ages) and separated from each other by at least 3 km to reduce vector spillover were selected. Inclusion criteria were age and anthropometry (for ivermectin, weight of ≥15 kg; for dihydroartemisinin–piperaquine, participants older than 6 months); willingness to comply with trial procedures; and written informed consent. Villages were randomised (1:1) to either the intervention (ivermectin [orally at 300–400 μg/kg per day for 3 consecutive days] and dihydroartemisinin–piperaquine [orally depending on bodyweight] plus standard control interventions) or the control group (standard control interventions) using computer-based randomisation. Laboratory staff were masked to the origin of samples. In the intervention group, three rounds of mass drug administration once per month with ivermectin and dihydroartemisinin–piperaquine were given during two malaria transmission seasons from Aug 27 to Oct 31, 2018, and from July 15 to Sept 30, 2019. Primary outcomes were malaria prevalence by qPCR at the end of the second intervention year in November 2019, and Anopheles gambiae (s l) parous rate, analysed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT03576313.

Findings

Between Nov 20 and Dec 7, 2017, 47 villages were screened for eligibility in the study. 15 were excluded because the baseline malaria prevalence was less than 7% (Figure 1). 32 villages were enrolled and randomised to either the intervention or control group (n=16 in each group). The study population was 10 638, of which 4939 (46%) participants were in intervention villages. Coverage for dihydroartemisinin–piperaquine was between 49·0% and 58·4% in 2018, and between 76·1% and 86·0% in 2019; for ivermectin, coverage was between 46·9% and 52·2% in 2018, and between 71·7% and 82·9% in 2019. In November 2019, malaria prevalence was 12·8% (324 of 2529) in the control group and 5·1% (140 of 2722) in the intervention group (odds ratio [OR] 0·30, 95% CI 0·16–0·59; p<0·001). A gambiae (s l) parous rate was 83·1% (552 of 664) in the control group and 81·7% (441 of 540) in the intervention group (0·90, 0·66–1·25; p=0·537). In 2019, adverse events were recorded in 386 (9·7%) of 3991 participants in round one, 201 (5·4%) of 3750 in round two, and 168 (4·5%) of 3752 in round three. None of the 11 serious adverse events were related to the intervention.

Interpretation

The intervention was safe and well tolerated. In an area with high coverage of standard control interventions, mass drug administration of ivermectin and dihydroartemisinin–piperaquine significantly reduced malaria prevalence; however, no effect of ivermectin on vector parous rate was observed.

Funding

Joint Global Health Trials Scheme.

Translation

For the French translation of the abstract see Supplementary Materials section.

Le texte complet de cet article est disponible en PDF.

Plan


© 2022  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 22 - N° 4

P. 519-528 - avril 2022 Retour au numéro
Article précédent Article précédent
  • Tuberculosis screening among ambulatory people living with HIV: a systematic review and individual participant data meta-analysis
  • Ashar Dhana, Yohhei Hamada, Andre P Kengne, Andrew D Kerkhoff, Molebogeng X Rangaka, Tamara Kredo, Annabel Baddeley, Cecily Miller, Satvinder Singh, Yasmeen Hanifa, Alison D Grant, Katherine Fielding, Dissou Affolabi, Corinne S Merle, Ablo Prudence Wachinou, Christina Yoon, Adithya Cattamanchi, Christopher J Hoffmann, Neil Martinson, Eyongetah Tabenyang Mbu, Melissa S Sander, Taye T Balcha, Sten Skogmar, Byron W P Reeve, Grant Theron, Gcobisa Ndlangalavu, Surbhi Modi, Joseph Cavanaugh, Susan Swindells, Richard E Chaisson, Faiz Ahmad Khan, Andrea A Howard, Robin Wood, Swe Swe Thit, Mar Mar Kyi, Josh Hanson, Paul K Drain, Adrienne E Shapiro, Tendesayi Kufa, Gavin Churchyard, Duc T Nguyen, Edward A Graviss, Stephanie Bjerrum, Isik S Johansen, Jill K Gersh, David J Horne, Sylvia M LaCourse, Haider Abdulrazzaq Abed Al-Darraji, Adeeba Kamarulzaman, Russell R Kempker, Nestani Tukvadze, David A Barr, Graeme Meintjes, Gary Maartens
| Article suivant Article suivant
  • Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial
  • Ganesh Kumar Rai, Tarun Saluja, Shipra Chaudhary, Dipesh Tamrakar, Piush Kanodia, Bishnu Rath Giri, Rajeev Shrestha, Surendra Uranw, Deok Ryun Kim, Jae Seung Yang, Il-Yeon Park, Seung-Eun Kyung, Sridhar Vemula, Jagadeesh Reddy E, Bomi Kim, Birendra Prasad Gupta, Sue Kyoung Jo, Ji Hwa Ryu, Ho Keun Park, Jong Hoon Shin, Yoonyeong Lee, Hun Kim, Jerome H Kim, Zenaida Reynoso Mojares, T Anh Wartel, Sushant Sahastrabuddhe

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.